2023-02-03: On February 3, 2023, Beijing time, Henlius announced that the results of the Phase I clinical study (ASTRUM-007) of Hans-like (Slurimab) combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma (ESCC) were published in the international authoritative journal Nature. Medicine
2+ search results for 'Baike Biologics'.
2023-02-03: Clinical Approval Overview of Class 1 Chemical Drugs In April 2019, a total of 17 Chinese Class 1 cyanide drugs received implied approval from the State Drug Administration (NMPA) for clinical trials, as shown in the following table: 1. HZ-A-018 HZ-A-018 is jointly developed by Hangzhou Hezheng
Load More
2+ search results for 'Baike Biologics'.
2023-02-03: On February 3, 2023, Beijing time, Henlius announced that the results of the Phase I clinical study (ASTRUM-007) of Hans-like (Slurimab) combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma (ESCC) were published in the international authoritative journal Nature. Medicine
NEWS.YAOZH
1 month ago
2 minutes read
Clinical Trends of Class 1 New Drugs in China in April 2019-News-Tianya Medicine
2023-02-03: Clinical Approval Overview of Class 1 Chemical Drugs In April 2019, a total of 17 Chinese Class 1 cyanide drugs received implied approval from the State Drug Administration (NMPA) for clinical trials, as shown in the following table: 1. HZ-A-018 HZ-A-018 is jointly developed by Hangzhou Hezheng
WUHANTY
1 month ago
8 minutes read